Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the thienothiopyran class and is structurally classified as an alpha amino acid derivative. It was developed as a nonphosphorus and nonpeptide inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme implicated in negative regulation of insulin signaling. By selectively inhibiting PTP1B through structure-based design—specifically targeting Asp48 for selectivity—the compound demonstrates potential utility in modulating insulin sensitivity and has been explored as a lead for antidiabetic drug development. The molecular formula is C10H9NO5S2 with an average mass of approximately 287.31 g/mol. It remains experimental with no approved indications or advanced clinical trials reported to date[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(oxalyl-amino)-4,7-dihydro-5h-thieno[2,3-c]thiopyran-3-carboxylic acid.